Subtitle

The FDA approved two indications for Enhertu (fam-trastuzumab deruxtecan) on May 15, 2026, for patients with HER2-positive early breast cancer. This approval was based on clinical results showing that the new drug achieved a higher complete pathologic response rate compared to existing treatments. Enabling effective treatment in the early stage can significantly contribute to improving long-term survival rates for patients. Enhertu is designated as a neoadjuvant therapy, playing a crucial role in reducing tumors before surgery, expanding surgical options, and lowering the risk of recurrence. This represents a clinically proven case of the latest antibody-drug conjugate technology. The HER2-targeted therapy market features competition between existing trastuzumab and newly emerged antibody-drug conjugates. Enhertu combines the potent cytotoxic agent deruxtecan to effectively destroy tumor cells. Therefore, it can provide a new option for patients who had minimal responses to existing treatments. From the patient's perspective, an increase in treatment options enables personalized approaches, and receiving powerful treatment in the early stage can reduce long-term treatment costs and side effects. This is expected to have positive ripple effects across the entire healthcare system. Overall, this approval demonstrates that biopharmaceutical companies can lead the market through innovative antibody-drug conjugate platforms. Expansion of indications to other cancer types is anticipated in the future, and investor interest in this technology is expected to rise.